Roche snatched up genomics research outfit CAPP Medical to get its hands on the company's cancer detection platform, continuing its M&A streak and strengthening its foothold in cancer R&D.
Roche sealed its $1.2 billion deal with Foundation Medicine, forging ahead with cancer R&D as it gains a majority stake in the company. Read more >>
Natera reeled in $55 million in private financing, adding fuel to its R&D engine as it develops its prenatal DNA screening test and expands the reach for its noninvasive diagnostic technology. Read more >>
POPULAR COMMENT THREADS
Liquid biopsy tests are gaining traction within the industry as a viable alternative to traditional screening methods for cancer. A recent report by financial services firm Cowen & Co. said annual sales for the tools could surpass $10 billion, and study results are also turning up positive data in favor of the tests. Read more >>
Amid increased demand for rapid at-home tests, LabCorp is planning to offer its products directly to consumers online without a doctor's order.
Point-of-care diagnostics are picking up steam in the industry, with companies rolling out mobile platforms and smartphone apps that can quickly identify diseases. VisualDx is taking a different approach, offering a quick diagnostic tool that uses images rather than text to help physicians screen for certain conditions.
Quest Diagnostics' Focus Diagnostics unit snagged an FDA OK for its quick strep test, a notch in the Quest's belt as it looks to revive sluggish sales and generate some upward momentum.
Roche's Ventana Medical Systems announced a companion diagnostic agreement centered around Astellas Pharma's cancer fighting ASP5878.
GE and Veracyte are teaming up for a research collaboration aimed at developing new tools for disease diagnosis. Neither side is revealing financial details, but San Francisco, CA-based Veracyte plans to combine its genomic technology with GE Healthcare's digital imaging technology to identify features from raw imaging data that could provide new diagnostic information.
From Our Sister Sites
Two years after going down in flames in a Phase III study for CD22-positive non-Hodgkin's lymphoma, Pfizer has helped resurrect hopes for top drug prospect inotuzumab ozogamicin, saying the drug hit its first primary endpoint for spurring hematologic remission in patients with CD22-positive acute lymphoblastic leukemia.
Fueled by strong sales for its latest cardio drug and a promising pipeline, Switzerland's Actelion says it's on the lookout for acquisitions but remains wary of paying the big premiums that have become commonplace in pharma.